Bio-Medical Applications Of West Virginia, Inc is a medicare approved dialysis facility center in Man, West Virginia and it has 13 dialysis stations. It is located in Logan county at 308 Huff Creek Highway, Man, WV, 25635. You can reach out to the office of Bio-Medical Applications Of West Virginia, Inc at (304) 583-7857. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Bio-Medical Applications Of West Virginia, Inc has the following ownership type - Profit. It was first certified by medicare in April, 2016. The medicare id for this facility is 512541 and it accepts patients under medicare ESRD program.
| Name | Bio-Medical Applications Of West Virginia, Inc |
|---|---|
| Location | 308 Huff Creek Highway, Man, West Virginia |
| No. of Dialysis Stations | 13 |
| Medicare ID | 512541 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 308 Huff Creek Highway, Man, West Virginia, 25635 | |
| (304) 583-7857 | |
| Not Available |
News Archive
Signalife, Inc. has announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled "Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body".
Researchers are pursuing an innovative and unexpected new avenue in the quest to fight antibiotic resistance: synthetic mucus. By studying and replicating mucus' natural ability to control pathogenic bacteria, the scientists hope to find new methods for combating infections.
Patients with chronic obstructive pulmonary disease who are infected with Pseudomonas aeruginosa have a worse clinical outcome and are more likely to be hospitalized than those without the infection, states recent research.
The TriZetto Group, Inc. today announced that Chinese Community Health Plan (CCHP) has successfully implemented several TriZetto systems, including the Facets®, NetworX Pricer® and Clinical CareAdvance® applications.
The international team studied almost all X chromosome genes in 208 families with learning disabilities - the largest screen of this type ever reported.
› Verified 5 days ago
| NPI Number | 1497122469 |
| Organization Name | Fresenius Medical Care Man Dialysis |
| Doing Business As | Bio-medical Applications Of West Virginia, Inc. |
| Address | 308 Huff Creek Highway Man, West Virginia, 25635 |
| Phone Number | (304) 583-7857 |
News Archive
Signalife, Inc. has announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled "Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body".
Researchers are pursuing an innovative and unexpected new avenue in the quest to fight antibiotic resistance: synthetic mucus. By studying and replicating mucus' natural ability to control pathogenic bacteria, the scientists hope to find new methods for combating infections.
Patients with chronic obstructive pulmonary disease who are infected with Pseudomonas aeruginosa have a worse clinical outcome and are more likely to be hospitalized than those without the infection, states recent research.
The TriZetto Group, Inc. today announced that Chinese Community Health Plan (CCHP) has successfully implemented several TriZetto systems, including the Facets®, NetworX Pricer® and Clinical CareAdvance® applications.
The international team studied almost all X chromosome genes in 208 families with learning disabilities - the largest screen of this type ever reported.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 10 |
News Archive
Signalife, Inc. has announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled "Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body".
Researchers are pursuing an innovative and unexpected new avenue in the quest to fight antibiotic resistance: synthetic mucus. By studying and replicating mucus' natural ability to control pathogenic bacteria, the scientists hope to find new methods for combating infections.
Patients with chronic obstructive pulmonary disease who are infected with Pseudomonas aeruginosa have a worse clinical outcome and are more likely to be hospitalized than those without the infection, states recent research.
The TriZetto Group, Inc. today announced that Chinese Community Health Plan (CCHP) has successfully implemented several TriZetto systems, including the Facets®, NetworX Pricer® and Clinical CareAdvance® applications.
The international team studied almost all X chromosome genes in 208 families with learning disabilities - the largest screen of this type ever reported.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 14 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 118 |
| Percentage of adult patients getting regular hemodialysis at the center | 90 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Signalife, Inc. has announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled "Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body".
Researchers are pursuing an innovative and unexpected new avenue in the quest to fight antibiotic resistance: synthetic mucus. By studying and replicating mucus' natural ability to control pathogenic bacteria, the scientists hope to find new methods for combating infections.
Patients with chronic obstructive pulmonary disease who are infected with Pseudomonas aeruginosa have a worse clinical outcome and are more likely to be hospitalized than those without the infection, states recent research.
The TriZetto Group, Inc. today announced that Chinese Community Health Plan (CCHP) has successfully implemented several TriZetto systems, including the Facets®, NetworX Pricer® and Clinical CareAdvance® applications.
The international team studied almost all X chromosome genes in 208 families with learning disabilities - the largest screen of this type ever reported.
› Verified 5 days ago
| Adult patients getting regular peritoneal dialysis at the center | 4 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 19 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Signalife, Inc. has announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled "Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body".
Researchers are pursuing an innovative and unexpected new avenue in the quest to fight antibiotic resistance: synthetic mucus. By studying and replicating mucus' natural ability to control pathogenic bacteria, the scientists hope to find new methods for combating infections.
Patients with chronic obstructive pulmonary disease who are infected with Pseudomonas aeruginosa have a worse clinical outcome and are more likely to be hospitalized than those without the infection, states recent research.
The TriZetto Group, Inc. today announced that Chinese Community Health Plan (CCHP) has successfully implemented several TriZetto systems, including the Facets®, NetworX Pricer® and Clinical CareAdvance® applications.
The international team studied almost all X chromosome genes in 208 families with learning disabilities - the largest screen of this type ever reported.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Bio-Medical Applications Of West Virginia, Inc with elevated calcium levels.
| Patients with hypercalcemia | 21 |
| Hypercalcemia patient months | 161 |
| Patients with Serumphosphor | 25 |
| Patients with Serumphosphor less than 3.5 mg/dL | 17 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 22 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 31 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
| Patients with Serumphosphor greater than 7 mg/dL | 13 |
News Archive
Signalife, Inc. has announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled "Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body".
Researchers are pursuing an innovative and unexpected new avenue in the quest to fight antibiotic resistance: synthetic mucus. By studying and replicating mucus' natural ability to control pathogenic bacteria, the scientists hope to find new methods for combating infections.
Patients with chronic obstructive pulmonary disease who are infected with Pseudomonas aeruginosa have a worse clinical outcome and are more likely to be hospitalized than those without the infection, states recent research.
The TriZetto Group, Inc. today announced that Chinese Community Health Plan (CCHP) has successfully implemented several TriZetto systems, including the Facets®, NetworX Pricer® and Clinical CareAdvance® applications.
The international team studied almost all X chromosome genes in 208 families with learning disabilities - the largest screen of this type ever reported.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 14 |
| Patient months included in arterial venous fistula and catheter summaries | 113 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 57 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 15 |
News Archive
Signalife, Inc. has announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled "Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body".
Researchers are pursuing an innovative and unexpected new avenue in the quest to fight antibiotic resistance: synthetic mucus. By studying and replicating mucus' natural ability to control pathogenic bacteria, the scientists hope to find new methods for combating infections.
Patients with chronic obstructive pulmonary disease who are infected with Pseudomonas aeruginosa have a worse clinical outcome and are more likely to be hospitalized than those without the infection, states recent research.
The TriZetto Group, Inc. today announced that Chinese Community Health Plan (CCHP) has successfully implemented several TriZetto systems, including the Facets®, NetworX Pricer® and Clinical CareAdvance® applications.
The international team studied almost all X chromosome genes in 208 families with learning disabilities - the largest screen of this type ever reported.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 10 |
| Hospitalization Rate in facility | (Not Available) |
| Hospitalization Rate: Upper Confidence Limit | |
| Hospitalization Rate: Lower Confidence Limit |
News Archive
Signalife, Inc. has announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled "Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body".
Researchers are pursuing an innovative and unexpected new avenue in the quest to fight antibiotic resistance: synthetic mucus. By studying and replicating mucus' natural ability to control pathogenic bacteria, the scientists hope to find new methods for combating infections.
Patients with chronic obstructive pulmonary disease who are infected with Pseudomonas aeruginosa have a worse clinical outcome and are more likely to be hospitalized than those without the infection, states recent research.
The TriZetto Group, Inc. today announced that Chinese Community Health Plan (CCHP) has successfully implemented several TriZetto systems, including the Facets®, NetworX Pricer® and Clinical CareAdvance® applications.
The international team studied almost all X chromosome genes in 208 families with learning disabilities - the largest screen of this type ever reported.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Bio-Medical Applications Of West Virginia, Inc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 15.1 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 34.2 |
| Readmission Rate: Lower Confidence Limit | 3.7 |
News Archive
Signalife, Inc. has announced that The United States Patent and Trademark Office has awarded to the company patent #7,299,083 entitled "Electrode For, And Method Of, Indicating Signal Characteristics At Particular Positions In A Patient's Body".
Researchers are pursuing an innovative and unexpected new avenue in the quest to fight antibiotic resistance: synthetic mucus. By studying and replicating mucus' natural ability to control pathogenic bacteria, the scientists hope to find new methods for combating infections.
Patients with chronic obstructive pulmonary disease who are infected with Pseudomonas aeruginosa have a worse clinical outcome and are more likely to be hospitalized than those without the infection, states recent research.
The TriZetto Group, Inc. today announced that Chinese Community Health Plan (CCHP) has successfully implemented several TriZetto systems, including the Facets®, NetworX Pricer® and Clinical CareAdvance® applications.
The international team studied almost all X chromosome genes in 208 families with learning disabilities - the largest screen of this type ever reported.
› Verified 5 days ago